JPMorgan Chase & Co. Reiterates Overweight Rating for ResMed Inc. (CHESS) (RMD)
ResMed Inc. (CHESS) (ASX:RMD)‘s stock had its “overweight” rating restated by analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Thursday. They currently have a $5.91 target price on the stock.
ResMed Inc. (ASX:RMD) traded down 0.36% during mid-day trading on Thursday, hitting A$5.580. The stock had a trading volume of 4,594,225 shares. ResMed Inc. has a 1-year low of A$4.680 and a 1-year high of A$5.940. The stock has a 50-day moving average of A$5.36 and a 200-day moving average of A$5.21. The company has a market cap of A$7.821 billion and a price-to-earnings ratio of 23.43.
ResMed Inc, (ASX:RMD) is a holding company for the ResMed Group.
Receive News & Ratings for ResMed Inc (CHESS) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc (CHESS) and related companies with Analyst Ratings Network's FREE daily email newsletter.